{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.4","upperLimit":"48.6","value":"41.9"},{"groupId":"OG001","lowerLimit":"11.4","upperLimit":"21.4","value":"15.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.","id":"OG000","title":"Mirvetuximab Soravtansine"},{"description":"Participants randomized to IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.","id":"OG001","title":"Investigator's Choice (IC) Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo).","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months","title":"Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}